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Abstract 
Purpose: To present and document the effectiveness of intravitreal ranibizumab in the 
treatment of patients with choroidal neovascularization due to butterfly-shaped pattern 
dystrophy (PD) of the macula.  
Methods: Three intravitreal ranibizumab injections of 0.5 mg/0.05 ml in monthly intervals 
were given to a patient with a previously diagnosed butterfly-shaped PD who subsequently 
developed subfoveal choroidal neovascularization on the right eye. The patient had 
previously received a combination of verteporfin/photodynamic therapy for a juxtafoveal 
choroidal neovascular membrane on the left eye.  
Results: At the end of the treatment course, there was significant improvement of the 
patient’s vision and the appearance of the macula on optic coherence tomography and 
fluorescein angiography. Best-corrected visual acuity improved from 6/12 to 6/6 and retinal 
thickness at the macula decreased from 323 to 247 μm. No subretinal fluid remained. The 
patient is clinically stable over a 12-month follow-up period.  
Conclusions: Intravitreal ranibizumab seems to be an effective and safe option for the 
treatment of subfoveal choroidal neovascularization in patients with butterfly-shaped PD. 
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Introduction 
Pattern dystrophies (PD) are a heterogeneous group of inherited disorders of the 
retinal pigment epithelium which usually appear in middle life, affecting both eyes, 
predominantly at the macula and are considered to have a chronic progressive course, 
although in most patients functional vision is preserved in later life. Butterfly-shaped 
PD was initially described by Zhang et al. [1] as a relatively benign pigmentary 
dystrophy of the fovea affecting the retinal pigment epithelium. It has been linked to 
mutations on the RDS/peripherin gene on chromosome 6p21. Although uncommon, the 
disease may progress significantly over time and some patients might develop visual 
impairment due to atrophic changes or the development of a choroidal neovascular 
membrane (CNVM) at the macula [1, 2]. 
Case Presentation 
In 2004, a 58-year-old female patient presented at the retina clinic with symptoms of mild 
bilateral distortion, especially of the left eye, and difficulty in reading. Clinical examination, fundus 
fluorescein angiogram (FFA), and electrophysiology testing were performed. The electroretinogram 
was normal, but the electrooculogram was subnormal. The diagnosis of butterfly-shaped PD was 
established due to clinical phenotype and investigation results (fig. 1). On the left eye, the FFA 
revealed a juxtafoveal CNVM and was treated with a combination of verteporfin and photodynamic 
therapy (PDT) which, at the time, was considered to be the best treatment option. After the treatment, 
the CNVM was obliterated, and the patient was stabilized and put on a regular follow-up until his 
discharge in 2007.  
In 2010, the patient returned to the retina clinic with decreased vision and distortion in the right 
eye this time. On examination, best-corrected visual acuity (BCVA) on a Snellen chart was 6/12 in the 
right eye and 6/6 in the left. The FFA and the optical coherence tomography (OCT) revealed the 
presence of an active subfoveal CNVM in the right eye with accumulation of subretinal fluid and 
increased retinal thickness (323 μm) (fig. 2). A decision was made to treat the patient with a course of 
three-monthly intravitreal ranibizumab injections (0.5 mg/0.05 ml). 
The patient gave her informed consent for all material and medical records presented in this case 
report. 
 
Results 
Following the course of three-monthly intravitreal ranibizumab injections of 0.5 
mg/0.05 ml, the retinal thickness decreased from 323 to 247 μm on OCT scan images, 
and no evidence of subretinal fluid or intraretinal fluid could be revealed clinically or 
on OCT scan (fig. 3). The repeated FFA did not reveal any late-phase hyperfluoroscence 
due to leakage from the CNVM. The patient’s BCVA improved from 6/12 to 6/9 (Snellen 
chart) immediately after the 3-monthly intravitreal ranibizumab injections of 0.05 
mg/0.05 ml. 
The patient was monitored in 4–6 weeks intervals with an OCT scan and clinical 
assessment was performed. Four months after the last intravitreal injection, the 
patient’s BCVA had improved to 6/6. He remained asymptomatic with no reactivation 
of the CNVM for over 12 months following the last ranibizumab intravitreal injection. 
The fellow eye which had previously been treated with PDT developed a juxtafoveal  
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atrophic scar, and the BCVA remained stable at 6/6 (Snellen chart). Interestingly, the 
patient’s BCVA seemed to improve the weeks following the last injection. We have 
observed similar outcomes in several patients treated with anti-vascular endothelial 
growth factor (anti-VEGF) injections for age-related CNMV in our department, and a 
possible explanation is that anatomical or OCT improvement could precede functional 
visual improvement in these patients. 
Discussion 
PDs are a group of retinal disorders which predominantly affect the retinal pigment 
epithelium and unless complicated with the development of atrophy or CNMV do not 
cause serious visual impairment [2, 3]. Previously, verteporfin/PDT was utilized for the 
treatment of CNMV in patients with PD. Results from these attempts showed that 
although PDT had a temporary advantageous effect on visual function, the thermal 
insult to the retinal pigment epithelium cells would inevitably lead to the development 
of a significant atrophic scar which eventually would cause long-term deterioration of 
vision [3, 4]. 
Promising results were recently published regarding the use of intravitreal 
bevacizumab for the treatment of subfoveal CNVM associated with PD. Parodi et al. [5] 
studied a series of patients who were treated with a course of intravitreal bevacizumab 
for a period of more than 2 years and managed to document significant and sustainable 
improvement in terms of both BCVA and retinal thickness. That study added further 
data to earlier reports of an advantageous effect of bevacizumab in PD-associated 
CNVM [6]. Furthermore, Gallego-Pinazo et al. [7] very recently published a series of 
female patients diagnosed with adult-onset foveomacullar vitelliform dystrophy-
related CNVM in whom short-term promising results regarding BCVA were 
documented. 
In our case, the use of a standard loading dose of three intravitreal ranibizumab 
injections in a female patient with subfoveal CNVM due to butterfly-shaped PD led to a 
remarkable improvement in vision from 6/12 to 6/6 (Snellen chart), significant 
reduction of retinal thickness, and a normalization of the macular appearance on OCT. 
The fellow eye which was previously treated with PDT for a juxtafoveal CNVM 
developed an atrophic scar; however, vision remained stable and satisfactory (6/6 on 
Snellen chart). 
It is well documented in the literature that CNVM due to non-age-related macular 
degeneration conditions, such as in high myopia, respond better when treated with 
anti-VEGF intravitreal injections [8, 9]. Our patient remains stable with no evidence of 
reactivation of the condition 12 months following the last intravitreal ranibizumab (0.5 
mg/0.05 ml) injection and there is also a number of small series of non-age-related 
CNVM where even one intravitreal anti-VEGF injection was satisfactory to control the 
CNVM and stabilize the patient’s vision for a substantial amount of time [10, 11]. The 
patient is undergoing frequent monitoring (every 2 months) and although clinically 
stable up to now, recurrence of the condition cannot be excluded. 
This report adds some more valuable data to the recently published promising good 
results regarding the use of bevacizumab and ranibizumab in other PD-related CNVM.  
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To the best of our knowledge, this is the first report on the use of ranibizumab in 
butterfly-shaped PD-related CNVM. With the current evidence, it seems that both 
bevacizumab and ranibizumab are reliable and effective choices for the treatment of 
subfoveal PD-related CNVM as an alternative to the previously used combination of 
verteporfin/PDT. However, longer follow-up time, higher number of patients, as well as 
safety profile assessments are needed in future studies. 
Disclosure Statement 
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Fig. 1. FFA showing the typical butterfly pattern dystrophy. 
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Fig. 2. Right eye showing late leakage on FFA due to CNVM and left eye showing a well demarcated 
area of atrophy temporarily to the left macula as a result of PDT. 
 
 
 
Fig. 3. OCT on the right before the course of anti-VEGF treatment and OCT on the left following a 
course of three anti-VEGF intravitreal injections. 
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